Clinical Review Report

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Rivaroxaban (Xarelto): Treatment of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and Prevention of Recurrent DVT and PE [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.

Rivaroxaban (Xarelto): Treatment of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and Prevention of Recurrent DVT and PE [Internet].

Show details

Contents

< Prev Next >

Clinical Review Report

Drug	rivaroxaban (Xarelto)
Indication	Treatment of venous thromboembolic events (deep vein thrombosis [DVT], pulmonary embolism [PE]) and prevention of recurrent DVT and PE
Listing request	Use of Xarelto (15 mg and 20 mg tablets) for the treatment of pulmonary embolism for up to six (6) months.
Manufacturer	Bayer Inc.

ABBREVIATIONS

EXECUTIVE SUMMARY

1. INTRODUCTION

2. OBJECTIVES AND METHODS

3. RESULTS

4. DISCUSSION

5. CONCLUSIONS

APPENDIX 1 PATIENT INPUT SUMMARY

APPENDIX 2 LITERATURE SEARCH STRATEGY

APPENDIX 3 EXCLUDED STUDIES

APPENDIX 4 DETAILED OUTCOME DATA

APPENDIX 5 VALIDITY OF THE NON-INFERIORITY MARGIN

APPENDIX 6 DEFINITIONS OF PRIMARY OUTCOMES USED IN THE EINSTEIN TRIALS

APPENDIX 7 SUMMARY OF OTHER STUDIES

REFERENCES

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK344336

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Rivaroxaban (Xarelto): Treatment of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and Prevention of Recurrent DVT and PE [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug. Clinical Review Report.
PDF version of this page (2.4M)